Your browser doesn't support javascript.
loading
Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer.
Milne, Roger L; Kuchenbaecker, Karoline B; Michailidou, Kyriaki; Beesley, Jonathan; Kar, Siddhartha; Lindström, Sara; Hui, Shirley; Lemaçon, Audrey; Soucy, Penny; Dennis, Joe; Jiang, Xia; Rostamianfar, Asha; Finucane, Hilary; Bolla, Manjeet K; McGuffog, Lesley; Wang, Qin; Aalfs, Cora M; Adams, Marcia; Adlard, Julian; Agata, Simona; Ahmed, Shahana; Ahsan, Habibul; Aittomäki, Kristiina; Al-Ejeh, Fares; Allen, Jamie; Ambrosone, Christine B; Amos, Christopher I; Andrulis, Irene L; Anton-Culver, Hoda; Antonenkova, Natalia N; Arndt, Volker; Arnold, Norbert; Aronson, Kristan J; Auber, Bernd; Auer, Paul L; Ausems, Margreet G E M; Azzollini, Jacopo; Bacot, François; Balmaña, Judith; Barile, Monica; Barjhoux, Laure; Barkardottir, Rosa B; Barrdahl, Myrto; Barnes, Daniel; Barrowdale, Daniel; Baynes, Caroline; Beckmann, Matthias W; Benitez, Javier; Bermisheva, Marina; Bernstein, Leslie.
Afiliación
  • Milne RL; Cancer Epidemiology and Intelligence Division, Cancer Council Victoria, Melbourne, Victoria, Australia.
  • Kuchenbaecker KB; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.
  • Michailidou K; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Beesley J; Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, UK.
  • Kar S; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Lindström S; Department of Electron Microscopy/Molecular Pathology, The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus.
  • Hui S; Cancer Division, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
  • Lemaçon A; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
  • Soucy P; Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington, USA.
  • Dennis J; Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
  • Jiang X; Donnelly Centre, University of Toronto, Toronto, Ontario, Canada.
  • Rostamianfar A; Genomics Center, Centre Hospitalier Universitaire de Québec Research Center, Laval University, Québec City, Québec, Canada.
  • Finucane H; Genomics Center, Centre Hospitalier Universitaire de Québec Research Center, Laval University, Québec City, Québec, Canada.
  • Bolla MK; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • McGuffog L; Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
  • Wang Q; Donnelly Centre, University of Toronto, Toronto, Ontario, Canada.
  • Aalfs CM; Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
  • Adams M; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Adlard J; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Agata S; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Ahmed S; Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands.
  • Aittomäki K; Center for Inherited Disease Research (CIDR), Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Al-Ejeh F; Yorkshire Regional Genetics Service, Chapel Allerton Hospital, Leeds, UK.
  • Allen J; Immunology and Molecular Oncology Unit, Istituto Oncologico Veneto (IOV), IRCCS, Padua, Italy.
  • Ambrosone CB; Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK.
  • Amos CI; Center for Cancer Epidemiology and Prevention, University of Chicago, Chicago, Illinois, USA.
  • Andrulis IL; Department of Clinical Genetics, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
  • Anton-Culver H; Personalised Medicine Team, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
  • Antonenkova NN; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Arndt V; Roswell Park Cancer Institute, Buffalo, New York, USA.
  • Arnold N; Center for Genomic Medicine, Department of Biomedical Data Science, Geisel School of Medicine, Dartmouth College, Lebanon, New Hampshire, USA.
  • Aronson KJ; Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Auber B; Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
  • Auer PL; Department of Epidemiology, University of California, Irvine, Irvine, California, USA.
  • Ausems MGEM; N.N. Alexandrov Research Institute of Oncology and Medical Radiology, Minsk, Belarus.
  • Azzollini J; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Bacot F; Institute of Clinical Molecular Biology / Department of Gynecology and Obstetrics, University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel, Germany.
  • Balmaña J; Department of Public Health Sciences and Cancer Research Institute, Queen's University, Kingston, Ontario, Canada.
  • Barile M; Institute of Human Genetics, Hannover Medical School, Hannover, Germany.
  • Barjhoux L; Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
  • Barkardottir RB; Zilber School of Public Health, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA.
  • Barrdahl M; Department of Medical Genetics, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Barnes D; Unit of Medical Genetics, Department of Preventive and Predictive Medicine, Fondazione IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), Istituto Nazionale dei Tumori (INT), Milan, Italy.
  • Barrowdale D; McGill University and Génome Québec Innovation Centre, Montréal, Québec, Canada.
  • Baynes C; Department of Medical Oncology, University Hospital, Vall d'Hebron, Barcelona, Spain.
  • Beckmann MW; Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia, Milan, Italy.
  • Benitez J; Bâtiment Cheney D, Centre Léon Bérard, Lyon, France.
  • Bermisheva M; Laboratory of Cell Biology, Department of Pathology, Landspitali, Reykjavik, Iceland.
  • Bernstein L; BMC (Biomedical Centre), Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
Nat Genet ; 49(12): 1767-1778, 2017 Dec.
Article en En | MEDLINE | ID: mdl-29058716
Most common breast cancer susceptibility variants have been identified through genome-wide association studies (GWAS) of predominantly estrogen receptor (ER)-positive disease. We conducted a GWAS using 21,468 ER-negative cases and 100,594 controls combined with 18,908 BRCA1 mutation carriers (9,414 with breast cancer), all of European origin. We identified independent associations at P < 5 × 10-8 with ten variants at nine new loci. At P < 0.05, we replicated associations with 10 of 11 variants previously reported in ER-negative disease or BRCA1 mutation carrier GWAS and observed consistent associations with ER-negative disease for 105 susceptibility variants identified by other studies. These 125 variants explain approximately 16% of the familial risk of this breast cancer subtype. There was high genetic correlation (0.72) between risk of ER-negative breast cancer and breast cancer risk for BRCA1 mutation carriers. These findings may lead to improved risk prediction and inform further fine-mapping and functional work to better understand the biological basis of ER-negative breast cancer.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Proteína BRCA1 / Predisposición Genética a la Enfermedad / Polimorfismo de Nucleótido Simple / Mutación Tipo de estudio: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Nat Genet Asunto de la revista: GENETICA MEDICA Año: 2017 Tipo del documento: Article País de afiliación: Australia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Proteína BRCA1 / Predisposición Genética a la Enfermedad / Polimorfismo de Nucleótido Simple / Mutación Tipo de estudio: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: Nat Genet Asunto de la revista: GENETICA MEDICA Año: 2017 Tipo del documento: Article País de afiliación: Australia
...